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A 76 \earoldiapanese man was admitted to the hospital
because of acute renal failure and hernaturia. During
a routine physical exam 6 months prior to admisson
the patient was found to have microscopic hematuria.
I-Ic ss as treated for presumed urinar tract infection.
but his urine analvs is continued to sho proteinuria
100 mgdI . 50—IOU red blood cells /HPF. 4—10 hvaline
casts per low power tield (LPF) and 5-20 ‘a hue blood
cell! high power field (HPF).
One month priorto admission the patient represented
to his primary care physician with a history of seven
kilogram unintentional weight loss over two months
as well as bilateral leg swelling, increased fatigue and
decrease in exercise tolerance. Laboratory abnormali
ties included an elevated BUN and Creatinine of 23
mg/dl and 1.9 mg/dl respectively, a hemoglobin of
11.7 g!dl. ahematocrit of35.6 with normal indices, a
white count of I X.8 x l0/mm without a left shift and
a thrombocvtosis of 737 x I 0d!mm. An urinanalvsis
revealed proteinuria I 100 mg!dl). significant blood
‘a ith > 100 RBCHPF. 3-10 hyline castsiLPF.5-20
WBCHPF arid man bacteria.
One week prior to admission the patient was referred
to a nephrologist due to hematuria and progressive
renal failure with a BUN of 32 mg/dl and a creatinine
of 2.3 mg/dl - His anemia had worsened (Hb 9.6 g!dl.
hematocrit 28,7Uf) and his white count continued to
rise (23.2 x 103/mm) His serum iron level and total
iron binding capacity ‘acre both low (15 mcgdl. 164
mcgdl respectivelv ‘a hi Ic the serum ferritin level ‘a as
elevated 1050 mc mli Reticulocvtecount ‘a as normal
and an dc’ ated Flapioizlobin was elevated. PS:\ ‘a as
0.3 ng!ml.
Further evaluation sho’a ed a 24 hour creatinine
clearance of 25 ml miii and a protein excretion of
2.Ut mg24 hours. Tests for hepatitis A. B. C. anti
glomerular basement membrane antibodies. ANA,
CS. C4 levels and a c-ANCA (Anti-Protcinase-3) of
1 .2 Units/mI were normal. His p-ANCA was strongly
positive with> 100 Units/nil (normal <9 U/mlL ESR
was elevated with 59 mm/hr. Serum electrophoresis
shos ed hypoalbuminemia and a high alpha-I . gamma
traction with a normal beta fraction and no mc clonal
bands. The urine elecimophoresis shoe cr1 proteinuria
with predominance of the albumin fraction. Because
of rapidl progressive glomerulonephritis he was
admitted to the hospital.
Further review of srstems revealed a chronic non—
producti e cough. He denied an Orver. chills, night
sweats. sinus or hearing probletiis. henioptvsis. nose
bleeding. chest pain. palpitations. nausea. vomiting.
constipation. diarrhea. niusculoskeletal pain, arthritis.
d suria. rash or pruritus.
Past medical history included hypertension,COPD.
hypercholesteremia and hperuricemia. The patient
had surgery for a spontaneous pneumothorax 2 years
ago. His medications included Allopurinol and Ator
vastatin.
Physical exam on admission showed an alert older
gentleman in mild respiratory distress. His blood pres
sure was I 40!7OmmHg with a heart rate of 6/mm.
Temperature was 39.3CC and his oxygen saturation
was 93L on room air. Several scars were noted on
the right chest from his prior surgery. There were no
petechiae. purpura or other rashes. Head. ear, nose
and throat exam ‘a as normal. Auscultation ofthe chest
revealed a mild expirator\ wheeze ‘a ith a prolonged
expiratorv phase. Abdominal including a guaic stool.
cardiac and neurologic exam sxere normal. There ‘a as
moderate bilateral pitting edema up to both knees
present.
Chest X-Ray on admission showed a mild conges
tive pattern with cardiomegaly and small right pleural
effusion.
The patient was admitted to the hospital and started
on ceftriaxone. Tuberculosis ‘a as considered and the
patient ‘a as placed on into respirator\ isolation. Sub
sequentlr his PPD. blood— and spinum cultures ‘a crc
all negatin e including AFB. The patient continued to
hax e persistent fver up to 39.4 °C.
Due to his acute renal t/nlure and positive p-ANCA
he undem’a ent a left kidne\ biopsy on hospital da
The kidneys appeared normal during the kidney
biopsy.
The patient was treated with Methylprednisolone
750 mg IV daily for 3 doses followed by Prednison
80 mg per day that was initiated because of the high
suspicion for rapid progressis e glomeruloncphmitis
184
The biopsy subsequently shosed segmental necrotizing gloineru
lonephntis (GN with focal necrotizing arteritis most consistent with
pauci—immnnc glomerulonephritis. Immunofluorescence did not
show signilicant immune comple\ deposits. 5-6 out of IX glomeruli
had glohal cellularcrescent tormation and moderate tubulointerstitial
necrosis with mononuclearinliltrateon lieht microscopv.The findings
on election microscopy conlirmed the ones from light mircoscop\.
O erall these findings are compatible oh the diagnosis of small
essl asculitis. There v as no report of necrotitingr granulomas.
Because of the biops results and his posit. ix e p-ANCA the diag
nosis of microscopic polarterntis nodosa PAN was most likely.
The l)itieit was also started on I O() mg Cvclophosphamide orall\
The patient became afebrile after the first dose of steroids, lie v as
started on Vitamin D and Calcium supplements to prevent steroid
induced osteoporosis. Trimethoprim—Sul famethoxazole was initi
ated for PCP prophylaxis as well as a small additional treatment
benefit. His creatinine peaked at 3.5 rng/dl before returning to his
preadmission level. His WBC count also improved. His anemia re
mained stable and the patient was discharged on Cyclophospharnide
and Prednisone, The patient expired one year later with a normal
creatinine due to unrelated respiratory failure,
Discussion
Asvmptoniatic microscopic heinatLiria has a broad differential
diagnosis ranging from benign conditions such as vicorous exer—
cisc. sexual activity, menstruation over urinar tract infections and
nephrolithiasis to serious conditions such as glomerulonephritis or
cancer. A repeat urinanalxsis is recommended to see if’the hematuria
is persistent and to guide further evaluation Afollow up in 6 months
in case of isolated glomerular heniaturia is reasonable to check for
the development of proteinuria or renal insufficiency.
The combination of hematuria and protemnuria suggested a gb—
merular site ot the bleeding and nonglomerularcauses like neoplasm.
nephrolithiasis. cv sticdiseasc. papillar necrosis ormetaholic reasons
crc unlikely. The urinanalvsis suggested a nephritic svndm’om. The
rapid progression of symptoms and accompanying renal failure
represented a rapid progressive glomerulonephritis RPGN > which
is a clinical presentation of mans different glomerulonephritis.
There are three broad categories of nephritic syndrome. The first
is grouped tocether as immune—complex olomerulonephropathies
and includes immune mediated lg—A nephritis. membi’ano—prolifera—
live ON and postinfectious ON. The history did not re cal a prior
acute respiratory or abdominal infection which may suggest Ig-A
nephropathy the most common form of glomerular hematnria. Al
though he presented with symptoms of pneumonia the time course
does not suggest postinfectious glomerulonephritis. On physical
exam and history there were also no signs suggesting secondary
causes such as systemic lupus ervthematosus (SLE) or other rheu
matological diseases. Diagnostic workup for postinfectious ON
with Antistreptolysin 0 +‘- anti-deoxvribonuclease B and C3 was
negative. SLE was unlikely with normal levels of C4 .ANA and
C3 which in contrast to postinfectious ON remains low after 2—3
months.
Memhranoprolifcrati cON associated with HCV and crvoglohu—
ins were ruled out. The second category of nephritc syndrome are
the anti—basement glomernlonephropathies including Goodpasttn’e’s
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syndrome and localized anti-GBM disease which should be suspected
in patients with concomitant lung involvement as in this ease Anti—
glomerular basement antibodies were negative.
The third category is erouped under ‘small es’el vasculitis or
pauci—immune disease (due to irtuallv no antibody deposition in
the nephron ( and consists of three major entities with \Vegener
granulomatosis. Churg—Straus’, syndrome and microscopic po1 —
angiitis, The\ are all closeE related and distinct from pol arteritis
nodosa, Thetriad of symptoms include systemic necrotizing angiitis,
necrotizing inflammation of the respiratory tract and necrotizing
glomerulonephritis. The original description of the Churg-Strauss
syndrome included asthma, eosinophilia. granulomatous inflamma
lion, necrotizing systemic \ asculitis and necrotizing glomerulone—
phritis. To distinguish bet een the other t o entities p—A\CA for
microscopic polvangi tis and c-ANCA for Wegener granuloniatosis
should be ordered. Our patient had positive p—ANCA suggesti\ e of
microscopic P.-\N (ni-PAN . Even with this positive .ANCA con
stellation the diagnosis of rn—PAN is not definite. Nonetheless. the
treatment ofWG and m-PAN is the same2.in rn-PAN approximately
70% have ANCA. It is useful in supporting the diagnosis when the
clinical setting is suggestive of ni-PAN, Histopathology remains
the gold standard for diagnosis. A negative ANCA assay does not
exclude ANCA-assoeiated vasculitis (I0-50 may be negative )‘.
ANCA may also be used to monitor disease activity7,
In rnostcases.delinitediagnosis is rnadeh\ kidney biopsr .AI.adne
biopsy is es aluated in three different modalities: light microscopy.
immunotluorescence and electron microscopy. Antibod deposits
can he found either subepithelial (membranous and postinfectious
GN). subendothelial (SEE) or in the mesangium ( Ig—A nephropa—
thy). A report of neerotizing granulomas would he more suggestive
of granulomatosis’.
Since the Patient had pulmonary infiltrates on his initial presentation
in the hospital the question arises ifhe had systemic involvement of
the lung. Microscopic polyangiitis is the most common cause of the
pulmonarr —renal syndrome’. Sometimes a lung biopsy is perfbrmed
to confirm this suspicion. but was not done in our case. The patient
improved with treatment although it was unclear vhether this was
related to treatment of his COPD or his underlying vasculitis.
Epidemiology
There is little epidemiologic data for small vessel vasculitis because
of the rarity as well as the different classifications of the disease, In
a French study the estimated prevalence per 1 .000.000 adults was
90.3 for all 4 vasculitides, 30.7 for PAN. 25. I foir microscopic PAN.
23.7 for Wegenerand 0.7 forChurg-Strauss. The overall pre alence
\\ as 2,°times higherfor Europeans compared ith non—European’.
Results of pre inns studies suggested latitudinal differences. \ Oh
\Veenerheing more frequent in northern countries and microscopic—
PAN prevailing in the south . Ethnic variations and difterences
between rural and urban areas niieht also pla\ a role. The esti
mated prevalence rate per I .000.000 for microscopic PAN as Of
in a northern area of Germany, whereas no cases were found in the
southern part5.Conversely, Watts et al reported an annual incidence
of 8/1,000,000. The significantly higher pre alence observed for
Europeans ma infer a genetic susceptibility of Caucasians,
Pathophysiology
The ANCA associated vasculitides are an immune disorder with
inflammatory and specific immune responses against neutrophile
granule proteins. ANCA’s are directly involved in the pathologic
process by interaction with neutrophil and endothelial cells -. The
theorr is that .ANCA induce a release of cvtokines from leuko—
cvtes and thereby start an inllammator response s hich leads to
a necroticing vasculitis. Other cellular responses involving ‘1’ and
13—cells are not as elI Linderstood. hut certainl take part in the
pathogenetic process.
Treatment
Treatment ofANCA associated small-vessel vasculitis is dividedint(i
acute. maintenance and relapse phase’. Current induction therapy of
more severe cases as in our case starts often ith IV pulse steroids
(Meth Iprednisolone 7 mg/kg) to ameliorate symptoms, addition
of Csclophosphainide 2nig/kg P0 (lail orO.5 gim7 IV per month
therapr s ith a subsequent switch to oral steroids tollo s. This
therap leads to impro ement of t) percent of patients‘. Oral
Cyclophosphamide is more toxic due to accumulati\ e effects, but
the ad antage is less relapses during the treatment course2.
This patient had already a prognostic factor for poor renal out
come because he had renal failure on presentation7.The associ
ated glomerulonephritis is progressive if not treated prcmptly. For
severe life-threatening disease, plasmaphersis is another option,
Lntreated small vessel \ asculitis has a poor prognosis with 900
of the patients dying within two years. One third of the patients
develop relapse. hut two thirds of these patients respond to the same
initial treatment’’. Another therap option in less se crc disease
consists of Methotrexate772.Patients shoLild also he started on
Trimethoprim— Sulfaniethoxazole for PCP prophylaxis since it has
been shown that six percent of Patients develop this disease during
the immunosuppressive treatment with steroids and that preventing
it is cost—effective—42.
Maintenance treatment should involve a quicker taper of steroids
than in the past which as about one ear7 ‘‘. Once complete re
mission is achieved. cyclophosphamide is discontinued and either
threxate (which is an option only among those with a serum
creatinine concentration 2.0 mgidL 1 771imol’L I) orriathioprine is
initiated7 . Ifthere is a minor relapses during maintenance therap\.
a trial of increasing dose of corticoLeroids and immunosuppressive
agents can be considered. Atiother option is treating the disease with
the initial induction regimen in patients with more severe disease
and in those who are no longer on immunosuppressive therapy75.
Other options which has e to be considered with further progressive
disease include maintenance dialysis and renal transplantation. Future
medical options might include RIG, leflunoinide. mvcophenolate
niofetil and 1’NF—alpha.
Conclusion
The ditOreniial diagnosis of hematuria can include benign disease
to life-threatening diseases such as microscopic PAN: therefore
a systeniatic approach to the evaluation of hematuria needs to he
taken,
If the patient has clinical features suggesting glomerulonephritis.
a nephrologist should he ins olved earlr in the course. Treatment (if





“Heinaturia with... “,jrom p. /86
There are still questions which remain unsolved including the role of renal transplant
in patients with severe small vessel vasculitis or new therapeutic drug regimens which
might he less tOXiC.
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Classified Notices
To place a classified notice:
HMA members—As a benefit of membership. HMA
members may place a complimentary one-time clas
sified ad in HMJ as space is available.
Nonmembers,—Rates are $150 a Word with a
minimum of 20 words or $30. Not commissionable,
For more information call (808) 536-7702.
Office Space & Support Services
ALA MOANA BLDG— PHYSICIAN WANTED to share
space and support services. Interest in physical rehab.
preferred. We have unique time-share arrangements starting
at one halt-day per meek. Run your practice with no fixed
overhead. Contact Dr. Speers, REHABILITATION ASSOCI
ATES. 955-7244.
CT Consulting
STARTING A NEW PRACTICE? — CT CONSULT
ING. INC., provides business insight to effectively contract
mith healthplans. establish billing guidelines, interview staff
and coordinate other business functions. With 15+ years of
experience in the healthcare industry, CT Consulting adds
business savvy to your practice. Contact Catherine at (8081
330-7738, e-mail: cjcoo$gitin@ttawah.yr,000i.
Physician Wanted
PRIMARY CARE PHYSICIAN — HALF-TIME, University
Health Services Manoa, call Lily Ning MD at (808) 956-8965
for information,
Physician Wanted
EXPERIENCED PHYSICIAN NEEDED — PART-TIME,
in a family practice clinic, mill be working with an NP. Send
CV to (808) 689-7115.
Honolulu Practice Available
ACTIVE ONGOING — INTERNAL MEDICINE PRACTICE,
in urban Honolulu available as physician plans to retire.
Contact: (808) 951-9931
Surfer’s Medica’ Association: Conference in Biarritz, France
The first European meeting of the SMA wig be held from September30 to October 9,2005.
The conference would be of interest to physicians and allied hea.lthcare professionals who
treat surfers as patients and/or who are surfers themselves.
The conference program will include presentations by aH attendees to update the status
of the healthcare/surfi’ng interfac’e pius networking with international colleagues. Addi
tional details are available on the SMA website (www.damoon.net) in the events section,
The conference registration fee of $2,200 USD includes one oceanfront room (based on
double occupancy) for ten nights, three meals per day and ground transport each day to
selected surf spots,
To enroll, make check payable to SMA:BlARRfl and mail to 1330 Ala Moana Blvd., #2101,
Honolulu, HI 96814, Questions may be directed to the conference chairperson,
Dr. Bob Spe ers at gpeers@lava.ret.
